Phase 3 Parkinson's Disease clinical trials

12 recruiting Phase 3 parkinson's disease studies in the US. What trial phases mean

Other phases

RecruitingPhase 3NCT06345729

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Sponsor: Merck Sharp & Dohme LLC

Bakersfield, CA · Beverly Hills, CA · Stamford, CT · +12 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Gilbert, AZ · Tucson, AZ · Fullerton, CA · +51 more sites

RecruitingPhase 3NCT06170788

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Sponsor: Merck Sharp & Dohme LLC

Phoenix, AZ · Burbank, CA · Grand Junction, CO · +12 more sites

RecruitingPhase 3NCT06312176

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Sponsor: Merck Sharp & Dohme LLC

Chandler, AZ · Gilbert, AZ · Fullerton, CA · +43 more sites

RecruitingPhase 3NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Sponsor: Merck Sharp & Dohme LLC

Mobile, AL · Chandler, AZ · Duarte, CA · +36 more sites

RecruitingPhase 3NCT06952504

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Sponsor: Merck Sharp & Dohme LLC

Mobile, AL · Anchorage, AK · Irvine, CA · +50 more sites

RecruitingPhase 3NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Sponsor: Merck Sharp & Dohme LLC

Gilbert, AZ · Phoenix, AZ · Tucson, AZ · +61 more sites

RecruitingPhase 3NCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Sponsor: AstraZeneca

Tucson, AZ · Little Rock, AR · Duarte, CA · +60 more sites

RecruitingPhase 3NCT07216703

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Sponsor: Merck Sharp & Dohme LLC

Birmingham, AL · Anchorage, AK · Irvine, CA · +27 more sites

RecruitingPhase 3NCT07174310

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Sponsor: Hoffmann-La Roche

Birmingham, AL · Phoenix, AZ · Fullerton, CA · +50 more sites

RecruitingPhase 3NCT04664634

A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's

Sponsor: Northwestern University

Evanston, IL

RecruitingPhase 3NCT06944522

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Sponsor: BlueRock Therapeutics

Scottsdale, AZ · Sun City, AZ · Little Rock, AR · +31 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.